The impact of scaling-up combination antiretroviral therapy on patterns of mortality among HIV-positive persons in British Columbia, Canada

Journal of the International AIDS Society

Volumn 18, Issue 1, 2015, Pages

  Lima, Viviane Dias ^a,b   Eyawo, Oghenowede ^a,c   Ma, Huiting ^a   Lourenco, Lillian ^a   Chau, William ^a   Hogg, Robert S ^a,c   Montaner, Julio S G ^a,b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

British Columbia; Canada; Clinical outcomes; Life expectancy; Mortality rate; PLHIV; Standardized mortality ratios; Treatment as prevention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CANADA; CLINICAL FEATURE; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCALE UP; SEX DIFFERENCE; STANDARDIZED MORTALITY RATIO; TREATMENT OUTCOME; BRITISH COLUMBIA; COMBINATION DRUG THERAPY; EPIDEMIOLOGY; HIV INFECTIONS; MIDDLE AGED;

ADULT; AGED; ANTI-HIV AGENTS; BRITISH COLUMBIA; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84943745870     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.1.20261     Document Type: Article

References (37)

1. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349(9061):1294.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, D'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22-9.
3. Van Sighem AI, Gras LA, Reiss P, Brinkman K, De Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24(10):1527-35.
4. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007;46(1):72-7.
5. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355.
6. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293-9.
7. Joy R, Druyts EF, Brandson EK, Lima VD, Rustad CA, Zhang W, et al. Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr. 2008;47(4):500-5.
8. Miller CL, Spittal PM, Wood E, Chan K, Schechter MT, Montaner JS, et al. Inadequacies in antiretroviral therapy use among Aboriginal and other Canadian populations. AIDS Care. 2006;18(8):968-76.
9. Simard EP, Fransua M, Naishadham D, Jemal A. The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007. Arch Intern Med. 2012;172(20):1591-8.
10. Montaner JS, Lima VD, Harrigan PR, Lourenco L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. PLoS One. 2014;9(2):e87872.
11. British Columbia Centre for Excellence in HIV/AIDS (BCCfE). STOP HIV/AIDS 2012 [cited 2014 Dec. 8]. Available from: http://cfenet.ubc.ca/stop-hiv-aids/about
12. Montaner JS, Hogg RS, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534):531-6.
13. Montaner JS. Treatment as prevention - a double hat-trick. Lancet. 2011;378(9787):208-9.
14. Nosyk B, Montaner JS, Colley G, Lima VD, Chan K, Heath K, et al. The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. Lancet Infect Dis. 2014;14(1):40-9.
15. British Columbia Centre for Disease Control. HIV in British Columbia: annual surveillance report 2013. 2015 [cited 2014 Dec. 4]. Available from: http://www.bccdc.ca/NR/rdonlyres/5711AA53-7399-43DC-8BB3-135BB9AFB4 7E/0/H IV-Annual-Report-2013FINAL. PDF
16. British Columbia Centre for Excellence in HIV/AIDS (BCCfE). Therapeutic guidelines Vancouver: BCCfE; 2013 [cited 2014 Dec. 4]. Available from: http://cfenet.ubc.ca/therapeutic-guidelines
17. Hammer SM, Eron JJ, Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555-70.
18. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321-33.
19. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387-402.
20. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292(2):251-65.
21. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296(7):827-43.
22. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288(2):222-35.
23. Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55(4):460-5.
24. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50(5):529-36.
25. BC Stats. BC Stats Home Victoria, BC: BC Stats; 2014 [cited 2014 Dec. 4]. Available from: http://www.bcstats.gov. bc.ca/Home.aspx
26. British Columbia Vital Statistics Agency. Vital Statistics Agency: British Columbia Vital Statistics Agency; 2014 [cited 2014 Dec. 4]. Available from: http://www.vs.gov. bc.ca/index.html
27. McDonald JH. Handbook of biological statistics. Baltimore, USA: Sparky House Publishing; 2009.
28. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.
29. Chiang CL. The life table and its construction. Introduction to stochastic processes in biostatistics. New York: Wiley; 1968.
30. Gunthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):410-25.
31. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
32. Carter AJ, Bourgeois S, O'Brien N, Abelsohn K, Tharao W, Greene S, et al. Women-specific HIV/AIDS services: identifying and defining the components of holistic service delivery for women living with HIV/AIDS. J Int AIDS Soc. 2013;16:17433, doi: http://dx.doi.org/10.7448/IAS.16.1.17433
33. Momentum Health Study. 2015 [cited 2014 Dec. 4]. Available from: http://www.momentumstudy.ca
34. The Urban Health Research Initiative. 2015 [cited 2014 Dec. 4]. Available from: http://uhri.cfenet.ubc.ca
35. The Gender and Sexual Health Initiative. 2015 [cited 2014 Dec. 4]. Available from: http://www.gshi.cfenet.ubc.ca
36. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) study. BMJ. 2011;343:d6016.
37. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155(4):209-16.